Nijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. This final extension of its Series A was co-led by new investors INKEF Capital and Aglaia Oncology Fund II. Existing shareholders also participated in this round, bringing the total Series A funding to US$ 10.5 million.
The proceeds of this financing will be used to progress several lead product candidates, through preclinical studies towards clinical development and for further expansion of the management team.
InteRNA has miRNA compounds under development with proven pleiotropic effects across multiple oncogenic signaling pathways and cellular processes. Therefore, these compounds have the potential to become the next generation of drugs for the treatment of a broad spectrum of different human cancers.
In parallel to this funding, InteRNA is pleased to announce that Hans Schikan, former CEO of Prosensa, has become the new chairman of its Supervisory Board. Further joining him and current member Mark Vaeck (CEO of Complix) on the Supervisory Board are Lucas de Breed and Karl Rothweiler for the new investors. The Board is further completed by Samuel Gerssen (for Waterman 40 Holding) and new independent member Brian Bronk (Sanofi Sunrise, part of the Sanofi Global R&D organization).
“We are very pleased to have these new experienced Board members and professional investors on board. We are now fully geared up to progress development of our lead compounds and further validate the power of our platform. The strong Board and investor base provides us a great outlook on further funding for clinical trials”, said Roel Schaapveld, CEO of InteRNA Technologies.
Hans Schikan commented: “I am excited to chair the Supervisory Board of InteRNA. RNA therapeutics are coming of age and have the potential to form a novel class of drugs next to small molecules and antibodies. InteRNA takes a unique position in the miRNA field through its agnostic functional screening approach delivering miRNA drug candidates which regulate multiple genes across cancer pathways.’’
“With the maturation of miRNA as a novel therapeutic modality, we believe that InteRNA has a strong foundation to translate their proprietary collection of functionally-validated leads into a clinical pipeline of compelling drug candidates, with the aim to substantially impact care for cancer patients”, commented Lucas de Breed, PhD, of INKEF Capital.
About INKEF Capital
INKEF is an Amsterdam, the Netherlands, based venture capital firm that is focused on the long-term collaboration and active support of innovative technology companies. INKEF was founded in 2010 by Dutch pension fund ABP and with € 200 million under management, it is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportunities in Healthcare, Technology and IT/NewMedia and prefers to participate from series A round financing onwards. www.inkefcapital.com
About Aglaia Oncology Fund II
Aglaia is a venture capital firm based in Bilthoven, the Netherlands. Aglaia invests in companies with technologies for the prevention and treatment of cancer. With three funds under management, Aglaia focuses exclusively on oncology, and distinguishes from other funds through its early-stage commitment and hands-on involvement. Aglaia aims to translate groundbreaking research into commercially and clinically successful products. The clear combination of financial and social return gives form to impact investing. www.aglaia-biomedical.com
About InteRNA Technologies B.V.
InteRNA Technologies develops cancer therapeutics based on a broadly applicable proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. At present, InteRNA has established in vivo proof of concept for multiple pipeline candidates. The Company is pursuing a proactive partnership strategy to acquire appropriate delivery technologies for its products and expects to engage in corporate partnerships to progress several of its products into clinical development.
InteRNA Technologies was incorporated by Aglaia Oncology Fund I as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.
Roel Schaapveld, PhD, MBA
InteRNA Technologies B.V.
Nijmegen City Centre
6534 AB Nijmegen
Phone: +31 (0)24 352 96 33 / +31 (0)30 2532386